



## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

28<sup>th</sup> April 2023  
IOLCP/CGC/2023

### **National Stock Exchange of India Ltd**

Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

**Security Symbol: IOLCP**

### **BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai – 400 001

**Security Code: 524164**

**Subject: Outcome of the Board Meeting dated 28<sup>th</sup> April 2023**

Dear Sir,

Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on today i.e. 28<sup>th</sup> April 2023 has inter alia considered and approved:

1. The Audited Financial Results (Standalone & Consolidated) for the Quarter and Year ended 31st March 2023. M/s Ashwani & Associates (Firm Registration No. 000497N), Chartered Accountants, the Statutory Auditors of the Company have issued Auditors' Reports with an unmodified opinion on the Financial Results of the Company for the Financial Year ended 31st March 2023. The Financial Results along with Auditors Report thereon is enclosed herewith as **Annexure 1**.
2. The re-appointment of Mr Varinder Gupta as Managing Director of the Company, subject to shareholders approval at their ensuing Annual General Meeting for a period of five year with effect from 1<sup>st</sup> September 2023. Mr Varinder Gupta is not debarred from holding the office of director by virtue of any order of SEBI or any other such authority. The details as per SEBI Circular CIR/CFD/CMD/4/2015 dated 09.09.2015 are enclosed herewith as **Annexure 2**.
3. The re-appointment of M/s. Ashwani & Associates (Firm Registration No. 000497N), Chartered Accountants, Ludhiana as Statutory Auditors of the Company, subject to the approval of shareholders of the company at their ensuing Annual General Meeting, for second term of 5 years, from the conclusion of 36<sup>th</sup> Annual General Meeting till the conclusion of 41<sup>st</sup> Annual General Meeting. The details as per SEBI Circular CIR/CFD/CMD/4/2015 dated 09.09.2015 are enclosed herewith as **Annexure 2**.
4. Fixed the 36<sup>th</sup> Annual General Meeting (AGM) of the members of the Company to be held on the Thursday, 10<sup>th</sup> August 2023 through Video Conferencing/ Other Audio-Visual Means ("VC/OAVM") Facility.
5. Approved the closure of the Register of Members and Share Transfer from 4<sup>th</sup> August 2023 to 10<sup>th</sup> August 2023 (both days inclusive) for the purpose of 36<sup>th</sup> AGM of the Company.

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC00030  
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolep.com Website : iolep.com  
Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292





## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The above Audited Financial Results are also available on the website of the Company i.e. [www.iolcp.com](http://www.iolcp.com).

The meeting commenced at 11:50 AM and concluded at 1:20 PM.

This is for your information & record.

Thanking You,

Yours faithfully,  
For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh  
Vice President & Company Secretary





**Independent Auditor's Report on Quarterly and Annual Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
**Board of Directors of  
IOL Chemicals and Pharmaceuticals Limited**

**Opinion**

We have audited the accompanying Statement of Audited Standalone Financial Results for the Quarter/Year ended 31<sup>st</sup> March 2023 ("the statement") of IOL Chemicals and Pharmaceuticals Limited ("the Company") (CIN-L24116PB1986PLC007030) being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to explanations given to us, the Statement:

- (i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2023.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Statement**



These Standalone Financial Results, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited financial statements for the quarter and year ended March 31, 2023. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind-AS-34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

### **Auditors' Responsibilities for the Audit of the Statement**

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:





- Identify and assess the risks of material misstatement of standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone financial results, including the disclosures, and whether the standalone financial results present the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Place: Ludhiana  
Dated: April 28th, 2023

For and on behalf of  
**Ashwani & Associates**  
**Chartered Accountants**  
Firm Registration Number: 000497N  
  
Mehar Singh  
Partner  
UDIN: 23097549BGWLC3393





# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED 31 MARCH 2023

in ₹ Crore

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2023 (Audited)	31.12.2022 (Audited)	31.03.2022 (Audited)	31.03.2023 (Audited)	31.03.2022 (Audited)
	<b>Income:</b>					
I	Revenue from operations	587.21	523.48	572.49	2,217.11	2,184.02
II	Other Income	8.72	6.64	6.93	25.57	32.04
III	<b>Total income (I+II)</b>	<b>595.93</b>	<b>530.12</b>	<b>579.42</b>	<b>2,242.68</b>	<b>2,216.06</b>
	<b>Expenses:</b>					
	Cost of materials consumed	397.96	359.71	411.25	1,536.07	1,578.91
	Purchases of stock-in-trade	-	7.31	15.12	29.22	43.90
	Changes in inventories of finished goods, work-in-progress and stock in trade	(20.30)	5.10	2.35	(18.20)	(52.30)
	Employee benefits expense	42.02	41.84	36.85	168.21	141.30
	Finance costs	4.88	4.70	2.34	16.47	8.29
	Depreciation and amortization expenses	12.10	11.73	11.01	46.13	43.26
	Other expenses	71.74	66.48	63.80	275.29	215.93
	<b>Total Expenses (IV)</b>	<b>508.40</b>	<b>496.87</b>	<b>542.72</b>	<b>2,053.19</b>	<b>1,979.29</b>
V	Profit before exceptional items and tax (III-IV)	87.53	33.25	36.70	189.49	236.77
VI	Exceptional items	-	-	-	-	13.93
VII	Profit before tax (V-VI)	87.53	33.25	36.70	189.49	222.84
VIII	<b>Tax Expense:</b>					
	Current tax	18.58	9.83	8.74	46.26	57.01
	Deferred tax	3.68	(0.73)	0.21	3.25	0.17
	<b>Total tax expense</b>	<b>22.26</b>	<b>9.10</b>	<b>8.95</b>	<b>49.51</b>	<b>57.18</b>
IX	<b>Profit for the period (VII-VIII)</b>	<b>65.27</b>	<b>24.15</b>	<b>27.75</b>	<b>139.98</b>	<b>165.66</b>
X	<b>Other Comprehensive Income</b>					
A	Items that will not be reclassified to profit or loss					
(i)	Remeasurement of Defined benefit obligation	0.97	(0.39)	0.61	(0.51)	(1.32)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	(0.24)	0.09	(0.16)	0.13	0.33
B	Items that will be reclassified to profit or loss					
(i)	Net movement in effective portion of cash flow hedge reserve	0.08	0.13	(0.27)	0.24	0.51
(ii)	Income tax relating to items that will be reclassified to profit or loss	(0.02)	(0.03)	0.07	(0.06)	(0.12)
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>66.06</b>	<b>23.95</b>	<b>28.00</b>	<b>139.78</b>	<b>165.06</b>
XII	Paid-up equity share capital (Face value ₹10/- per share)	58.71	58.71	58.71	58.71	58.71
XIII	Other equity (Reserves excluding revaluation reserve)	1,447.84	1,405.28	1,331.56	1,447.84	1,331.56
XIV	Earning per equity share of ₹10/- each (for continuing and discontinued operations) (not annualised except for the year ended 31.03.2023 and 31.03.2022)					
	Basic and Diluted ₹	11.11	4.12	4.73	23.84	23.22

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolep.com Website : iolep.com  
 Regd. Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292







# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## STANDALONE SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

in ₹ Crore

Sr.No.	Particulars	Quarter ended			Year ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	<b>Segment Revenue</b>					
	(Net sale/income)					
	- Chemical	291.57	276.77	327.03	1,194.85	1,322.50
	- Pharmaceutical	367.72	303.19	296.97	1,258.53	1,008.32
	- Unallocated	9.37	8.61	6.56	30.44	28.62
	<b>Total</b>	<b>668.66</b>	<b>588.57</b>	<b>630.56</b>	<b>2,483.82</b>	<b>2,359.44</b>
	Less : Inter segment revenue	72.73	58.45	51.14	241.14	143.38
	<b>Net sales/income from operations</b>	<b>595.93</b>	<b>530.12</b>	<b>579.42</b>	<b>2,242.68</b>	<b>2,216.06</b>
2	<b>Segment Results</b>					
	Profit before tax and interest (from each segment)					
	- Chemical	10.88	(1.49)	(5.66)	19.57	59.26
	- Pharmaceutical	79.58	34.73	39.68	171.53	162.92
	<b>Total</b>	<b>90.46</b>	<b>33.24</b>	<b>34.02</b>	<b>191.10</b>	<b>222.18</b>
	Less: Interest	4.88	4.70	2.34	16.47	8.29
	Add: Other un-allocable income net off un-allocable expenditure	1.95	4.71	5.02	14.86	22.88
<b>Total Profit before tax &amp; Extraordinary items</b>	<b>87.53</b>	<b>33.25</b>	<b>36.70</b>	<b>189.49</b>	<b>236.77</b>	
3	<b>Segment Assets</b>					
	- Chemical	442.02	518.72	537.77	442.02	537.77
	- Pharmaceutical	1,104.07	971.79	945.34	1,104.07	945.34
	- Unallocated	474.52	571.74	477.18	474.52	477.18
	<b>Total Assets</b>	<b>2,020.61</b>	<b>2,062.25</b>	<b>1,960.29</b>	<b>2,020.61</b>	<b>1,960.29</b>
4	<b>Segment Liabilities</b>					
	- Chemical	157.18	222.43	272.74	157.18	272.74
	- Pharmaceutical	180.43	166.49	179.72	180.43	179.72
	- Unallocated	176.45	209.34	117.56	176.45	117.56
	<b>Total Liabilities</b>	<b>514.06</b>	<b>598.26</b>	<b>570.02</b>	<b>514.06</b>	<b>570.02</b>



*[Handwritten signature]*

Head Office : 85, Industrial Area 'A', Ludhiana, 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolep.com Website : iolep.com  
 Regd. Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292





# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## Standalone Balance Sheet as at 31-March-2023

Particulars	As at 31-Mar-2023 in ₹ Crore	As at 31-Mar-2022 in ₹ Crore
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property, Plant and Equipment	750.52	559.49
(b) Right of use assets	0.14	0.97
(c) Capital work-in-progress	81.40	102.03
(d) Other Intangible assets	0.65	0.18
(e) Intangible assets under development	8.24	3.17
(f) Financial assets		
(i) Investments	17.71	0.10
(ii) Other financial assets	233.87	205.34
(g) Other non-current assets	9.01	10.30
<b>Total non-current assets</b>	<b>1,101.54</b>	<b>881.58</b>
<b>2 Current assets</b>		
(a) Inventories	325.52	409.89
(b) Financial assets		
(i) Investments	2.56	2.37
(ii) Trade receivables	505.28	469.80
(iii) Cash and cash equivalents	0.96	1.12
(iv) Bank balances other than (iii) above	19.94	136.76
(v) Other financial assets	22.36	22.98
(c) Current tax assets (net)	1.75	0.91
(d) Other current assets	40.70	34.88
<b>Total current assets</b>	<b>919.07</b>	<b>1,078.71</b>
<b>TOTAL ASSETS</b>	<b>2,020.61</b>	<b>1,960.29</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	58.71	58.71
(b) Other equity	1,447.84	1,331.56
<b>Total equity</b>	<b>1,506.55</b>	<b>1,390.27</b>
<b>Liabilities</b>		
<b>1 Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	-	-
(ia) Lease liabilities	-	0.18
(b) Provisions	1.65	3.01
(c) Deferred tax liabilities (net)	56.36	53.18
(d) Other non-current liabilities	0.14	0.25
<b>Total non-current liabilities</b>	<b>58.15</b>	<b>56.62</b>
<b>2 Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	79.63	42.75
(ia) Lease liabilities	0.18	1.02
(ii) Trade payables		
(A) Total outstanding dues of micro enterprises and small enterprises	14.70	14.10
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	299.52	395.19
(iii) Other financial liabilities	36.00	30.02
(b) Other current liabilities	17.75	22.98
(c) Provisions	8.13	7.34
<b>Total current liabilities</b>	<b>455.91</b>	<b>513.40</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2,020.61</b>	<b>1,960.29</b>



*U.P.R.*

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

### Standalone Cash flow statement for the year ended 31-March-2023

Particulars	For the year ended 31-Mar-2023 in ₹ Crore	For the year ended 31-Mar-2022 in ₹ Crore
<b>Cash flow from operating activities</b>		
<b>Profit before tax</b>	<b>189.49</b>	<b>222.84</b>
<b>Adjustments for:</b>		
Depreciation and amortisation expense	46.13	43.26
Unrealised foreign exchange (Gain)/Loss on foreign currency rate fluctuation	(1.97)	(1.28)
Net (Gain)/Loss on fair valuation of investments measured at fair value through profit or loss	(0.01)	(0.02)
Subsidy Income amortized	(0.07)	(0.07)
Interest income on financial assets carried at amortized cost net of rent amortized during the period	(0.06)	(0.08)
Liabilities no longer required written back	(0.03)	(0.03)
Lease Liability Provision written back	-	(0.08)
Net (Gain)/Loss on Property, plant and equipment sold	0.33	0.24
Loss on Property, plant and equipment discarded	0.26	0.85
Interest expense	16.47	8.29
Interest income	(16.63)	(17.96)
	<b>44.42</b>	<b>33.12</b>
<b>Operating profit before working capital changes</b>	<b>233.91</b>	<b>255.96</b>
Changes in working capital:		
Increase/(Decrease) in trade payables and other liabilities	(105.34)	183.19
Decrease/(Increase) in trade and other receivables	(42.70)	(170.78)
Decrease/(Increase) in inventories	84.37	(114.75)
	<b>(63.67)</b>	<b>(102.34)</b>
<b>Cash generated from operations</b>	<b>170.24</b>	<b>153.62</b>
Income tax paid (net)	(47.10)	(62.58)
<b>Net cash flow from/(used in) operating activities (A)</b>	<b>123.14</b>	<b>91.04</b>
<b>Cash flow from investing activities</b>		
Purchase of property, plant and equipment including intangible assets and Capital work in progress	(211.29)	(153.29)
Proceeds from sale of property, plant and equipment	2.22	1.89
Purchase of investment	(17.81)	(1.24)
Interest received	17.71	18.60
<b>Bank balances not considered as cash and cash equivalents:</b>		
Decrease in deposit with banks, having original maturity more than three months	98.34	23.55
Increase in deposit with banks, in earmarked accounts to the extent held as margin money against borrowings and other commitments	(8.36)	(10.13)
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>(119.19)</b>	<b>(120.62)</b>
<b>Cash flow from financing activities</b>		
Proceeds/(Repayment) of current borrowings	36.88	42.75
Interest paid	(16.40)	(8.11)
Lease rent payments	(1.09)	(1.06)
Dividend paid on Equity shares	(23.50)	(35.22)
<b>Net cash flow from/(used in) financing activities (C)</b>	<b>(4.11)</b>	<b>(1.64)</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>(0.16)</b>	<b>(31.22)</b>
Cash and cash equivalents at the beginning of the year	1.12	32.34
Cash and cash equivalents at the end of the year *	<b>0.96</b>	<b>1.12</b>
* Comprises		
Balances with banks in current account	0.43	0.70
Cash on hand	0.53	0.42
	<b>0.96</b>	<b>1.12</b>



*Handwritten signature*

Head Office : 85, Industrial Area 'A', Ludhiana, 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



**Independent Auditors' Report on the Quarterly and Year to Date Audited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
**The Board of Directors of  
IOL Chemicals and Pharmaceuticals Ltd.**

**Opinion**


We have audited the accompanying Statement of Consolidated Financial Results of **IOL Chemicals and Pharmaceuticals Ltd.** CIN-(L24116PB1986PLC007030) (the "Company") and its subsidiaries (the Company and its subsidiaries together referred to as the "Group") for the quarter and year ended March 31, 2023 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) includes the results of the subsidiaries as given in the Annexure to this report;
- (ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2023.

**Basis for Opinion**

We conducted our audit of the consolidated financial statements in accordance with the standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act") and other applicable authoritative pronouncements issued by ICAI. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit of evidence obtained by us is sufficient





and appropriate to provide a basis for our audit opinion on the Consolidated Financial Statements.

### **Management Responsibilities for the Consolidated Financial Results**

These Consolidated Financial Results, which is the responsibility of the holding company's management and approved by the holding company's board of directors, have been prepared on the basis of the consolidated financial statements for the three months and year ended March 31, 2023. The Holding Company's management is responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated total comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind-AS prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are also responsible for maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been used for the purpose of presentation of consolidated financial statements by the Directors of the Holding Company, as aforesaid

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their own company or to cease operations, or have no realistic alternative but to do so.

The respective Boards of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected





to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of such controls. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the financial results present the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI Regulation 33(8) of the Listing Regulations to the extent applicable.



- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the directions, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors.

Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial results.

We communicate with those charged with governance of the Holding Company and such other entity included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Place: Ludhiana  
Dated: April 28th, 2023

For and on behalf of  
**Ashwani & Associates**  
**Chartered Accountants**  
Firm Registration Number: 000497N



Arvind Jain  
Partner  
Membership No.: 097549  
UDIN: 23097549BGWLCT4215



**ANNEXURE TO AUDITORS' REPORT**

**LIST OF ENTITIES**

1. IOL Foundation
2. IOL Life Sciences Limited
3. IOL Speciality Chemicals Limited





# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED 31 MAR 2023

in ₹ Crore

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
	<b>Income:</b>					
I	Revenue from operations	587.21	523.48	572.49	2,217.11	2,184.02
II	Other Income	8.73	6.65	6.93	25.61	32.04
III	<b>Total income (I+II)</b>	<b>595.94</b>	<b>530.13</b>	<b>579.42</b>	<b>2,242.72</b>	<b>2,216.06</b>
	<b>Expenses:</b>					
IV	Cost of materials consumed	397.96	359.71	411.25	1,536.07	1,578.91
	Purchases of stock-in-trade	-	7.31	15.12	29.22	43.90
	Changes in inventories of finished goods, work-in-progress and stock in trade	(20.30)	5.10	2.35	(18.20)	(52.30)
	Employee benefits expense	42.02	41.84	36.85	168.21	141.30
	Finance costs	4.88	4.70	2.34	16.47	8.29
	Depreciation and amortization expenses	12.11	11.75	11.01	46.16	43.26
	Other expenses	72.23	66.84	61.79	276.14	213.92
	<b>Total Expenses (IV)</b>	<b>508.90</b>	<b>497.25</b>	<b>540.71</b>	<b>2,054.07</b>	<b>1,977.28</b>
V	Profit before exceptional items and tax (III-IV)	87.04	32.88	38.71	188.65	238.78
VI	Exceptional items	-	-	-	-	13.93
VII	Profit before tax (V-VI)	87.04	32.88	38.71	188.65	224.85
VIII	<b>Tax Expense:</b>					
	Current tax	18.58	9.83	8.74	46.26	57.01
	Deferred tax	3.68	(0.73)	0.21	3.25	0.17
	<b>Total tax expense</b>	<b>22.26</b>	<b>9.10</b>	<b>8.95</b>	<b>49.51</b>	<b>57.18</b>
IX	<b>Profit for the period (VII-VIII)</b>	<b>64.78</b>	<b>23.78</b>	<b>29.76</b>	<b>139.14</b>	<b>167.67</b>
X	<b>Other Comprehensive Income</b>					
A	Items that will not be reclassified to profit or loss					
	(i) Remeasurement of Defined benefit obligation	0.97	(0.39)	0.61	(0.51)	(1.32)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.24)	0.09	(0.16)	0.13	0.33
B	Items that will be reclassified to profit or loss					
	(i) Net movement in effective portion of cash flow hedge reserve	0.08	0.13	(0.27)	0.24	0.51
	(ii) Income tax relating to items that will be reclassified to profit or loss	(0.02)	(0.03)	0.07	(0.06)	(0.12)
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>65.57</b>	<b>23.58</b>	<b>30.01</b>	<b>138.94</b>	<b>167.07</b>
XII	Paid-up equity share capital (Face value ₹10/- per share)	58.71	58.71	58.71	58.71	58.71
XIII	Other equity (Reserves excluding revaluation reserve)	1,449.01	1,406.95	1,333.57	1,449.01	1,333.57
XIV	Earning per equity share of ₹10/- each (for continuing and discontinued operations) (not annualised except for the year ended 31.03.2023 and 31.03.2022)					
	Basic and Diluted ₹	11.03	4.05	5.07	23.70	28.56

*Handwritten signature/initials*

Head Office : 85, Industrial Area 'A', Ludhiana, 141 003 (Punjab) India CIN - L24116PB1986PLC007030

Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com

Regd. Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India

Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India

Ph. : +91-1679 -285285-86, Fax : +91-1679-285292







# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

in ₹ Crore

Sr.No.	Particulars	Quarter ended			Year ended	
		31.03.2023 (Audited)	31.12.2022 (Audited)	31.03.2022 (Audited)	31.03.2023 (Audited)	31.03.2022 (Audited)
1	<b>Segment Revenue</b>					
	(Net sale/income)					
	- Chemical	291.57	276.77	327.03	1,194.85	1,322.50
	- Pharmaceutical	367.70	303.21	296.97	1,258.53	1,008.32
	- Unallocated	9.40	8.60	6.56	30.48	28.62
	<b>Total</b>	<b>668.67</b>	<b>588.58</b>	<b>630.56</b>	<b>2,483.86</b>	<b>2,359.44</b>
	Less : Inter segment revenue	72.73	58.45	51.14	241.14	143.38
<b>Net sales/income from operations</b>	<b>595.94</b>	<b>530.13</b>	<b>579.42</b>	<b>2,242.72</b>	<b>2,216.06</b>	
2	<b>Segment Results</b>					
	Profit before tax and interest (from each segment)					
	- Chemical	10.88	(1.49)	(5.66)	19.57	59.26
	- Pharmaceutical	79.58	34.73	39.68	171.53	162.92
	<b>Total</b>	<b>90.46</b>	<b>33.24</b>	<b>34.02</b>	<b>191.10</b>	<b>222.18</b>
	Less: Interest	4.88	4.70	2.34	16.47	8.29
	Add: Other un-allocable income net off un-allocable expenditure	1.45	4.35	7.03	14.02	24.89
<b>Total Profit before tax &amp; Extraordinary items</b>	<b>87.03</b>	<b>32.89</b>	<b>38.71</b>	<b>188.65</b>	<b>238.78</b>	
3	<b>Segment Assets</b>					
	- Chemical	442.02	518.72	537.77	442.02	537.77
	- Pharmaceutical	1,104.07	971.79	945.34	1,104.07	945.34
	- Unallocated	476.04	573.61	479.19	476.04	479.19
	<b>Total Assets</b>	<b>2,022.13</b>	<b>2,064.12</b>	<b>1,962.30</b>	<b>2,022.13</b>	<b>1,962.30</b>
4	<b>Segment Liabilities</b>					
	- Chemical	157.18	222.43	272.74	157.18	272.74
	- Pharmaceutical	180.43	166.49	179.72	180.43	179.72
	- Unallocated	176.80	209.54	117.56	176.80	117.56
	<b>Total Liabilities</b>	<b>514.41</b>	<b>598.46</b>	<b>570.02</b>	<b>514.41</b>	<b>570.02</b>

*UJee*



Head Office : 85, Industrial Area 'A', Ludhiana, 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## Consolidated Balance Sheet as at 31-March-2023

Particulars	As at 31-Mar-2023 in ₹ Crore	As at 31-Mar-2022 in ₹ Crore
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property, plant and equipment	751.02	559.49
(b) Right of use assets	0.14	0.97
(c) Capital work-in-progress	81.40	102.03
(d) Other Intangible assets	0.65	0.18
(e) Intangible assets under development	8.24	3.17
(f) Financial assets		
(i) Investments	17.41	-
(ii) Other financial assets	233.87	205.34
(g) Other non-current assets	9.01	10.30
<b>Total non-current assets</b>	<b>1,101.74</b>	<b>881.48</b>
<b>2 Current assets</b>		
(a) Inventories	325.52	409.89
(b) Financial assets		
(i) Investments	2.56	2.37
(ii) Trade receivables	505.28	469.80
(iii) Cash and cash equivalents	1.39	3.23
(iv) Bank balances other than (iii) above	20.44	136.76
(v) Other financial assets	22.38	22.98
(c) Current tax assets (net)	1.75	0.91
(d) Other current assets	41.07	34.88
<b>Total current assets</b>	<b>920.39</b>	<b>1,080.82</b>
<b>TOTAL ASSETS</b>	<b>2,022.13</b>	<b>1,962.30</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	58.71	58.71
(b) Other equity	1,449.01	1,333.57
<b>Total equity</b>	<b>1,507.72</b>	<b>1,392.28</b>
<b>Liabilities</b>		
<b>1 Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	-	-
(ia) Lease liabilities	-	0.18
(b) Provisions	1.65	3.01
(c) Deferred tax liabilities (net)	56.36	53.18
(d) Other non-current liabilities	0.14	0.25
<b>Total non-current liabilities</b>	<b>58.15</b>	<b>56.62</b>
<b>2 Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	79.63	42.75
(ia) Lease liabilities	0.18	1.02
(ii) Trade payables	314.22	409.29
(iii) Other financial liabilities	36.34	30.02
(b) Other current liabilities	17.76	22.98
(c) Provisions	8.13	7.34
<b>Total current liabilities</b>	<b>456.26</b>	<b>513.40</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2,022.13</b>	<b>1,962.30</b>



*Ure*

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292





# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

## Consolidated Cash flow statement for the year ended 31-March-2023

Particulars	For the year ended 31-Mar-2023 in ₹ Crore	For the year ended 31-Mar-2022 in ₹ Crore
<b>Cash flow from operating activities</b>		
<b>Profit before tax</b>	<b>188.65</b>	<b>224.85</b>
<b>Adjustments for:</b>		
Depreciation and amortisation expense	46.16	43.26
Unrealised foreign exchange (Gain)/Loss on foreign currency rate fluctuation	(1.97)	(1.28)
Net (Gain)/Loss on fair valuation of investments measured at fair value through profit or loss	(0.01)	(0.02)
Subsidy Income amortized	(0.07)	(0.07)
Interest income on financial assets carried at amortized cost net of rent amortized during the period	(0.06)	(0.08)
Liabilities no longer required written back	(0.03)	(0.03)
Lease Liability Provision written back	-	(0.08)
Net (Gain)/Loss on Property, plant and equipment sold	0.33	0.24
Loss on Property, plant and equipment discarded	0.26	0.85
Interest expense	16.47	8.29
Interest income	(16.67)	(17.96)
	<b>44.41</b>	<b>33.12</b>
<b>Operating profit before working capital changes</b>	<b>233.06</b>	<b>257.97</b>
<b>Changes in working capital:</b>		
Increase/(Decrease) in trade payables and other liabilities	(104.99)	183.19
Decrease/(Increase) in trade and other receivables	(43.07)	(170.78)
Decrease/(Increase) in inventories	84.37	(114.75)
	<b>(63.69)</b>	<b>(102.34)</b>
<b>Cash generated from operations</b>	<b>169.37</b>	<b>155.63</b>
Income tax paid (net)	(47.10)	(62.58)
<b>Net cash flow from/(used in) operating activities (A)</b>	<b>122.27</b>	<b>93.05</b>
<b>Cash flow from investing activities</b>		
Purchase of property, plant and equipment including intangible assets and Capital work in progress	(211.82)	(153.29)
Proceeds from sale of property, plant and equipment	2.22	1.89
Purchase of investment	(17.61)	(1.14)
Interest received	17.73	18.60
<b>Bank balances not considered as cash and cash equivalents:</b>		
Decrease in deposit with banks, having original maturity more than three months	97.84	23.55
Increase in deposit with banks, in earmarked accounts to the extent held as margin money against borrowings and other commitments	(8.36)	(10.13)
	<b>(120.00)</b>	<b>(120.52)</b>
<b>Net cash flow from/(used in) investing activities (B)</b>		
<b>Cash flow from financing activities</b>		
Proceeds/(Repayment) of current borrowings	36.88	42.75
Interest paid	(16.40)	(8.11)
Lease rent payments	(1.09)	(1.06)
Dividend paid on Equity shares	(23.50)	(35.22)
	<b>(4.11)</b>	<b>(1.64)</b>
<b>Net cash flow from/(used in) financing activities (C)</b>		
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>(1.84)</b>	<b>(29.11)</b>
Cash and cash equivalents at the beginning of the year	3.23	32.34
Cash and cash equivalents at the end of the year*	<b>1.39</b>	<b>3.23</b>
<b>* Comprises</b>		
Balances with banks in current account	0.86	2.81
Cash on hand	0.53	0.42
	<b>1.39</b>	<b>3.23</b>



*Handwritten signature*

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.  
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

### NOTES:

1. The above standalone and consolidated audited financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on 28<sup>th</sup> April 2023.
2. The financial results of the Company have been audited by the Statutory Auditors and prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. The Statutory Auditors have expressed an unmodified opinion on these results.
3. As per Ind AS 108- Operating Segments, the Company has two reportable Operating Segments namely Pharmaceuticals and Chemicals. The financial information for these segments have been provided in Financial Results as per Ind AS 108- Operating Segments.
4. As IOL Life Sciences Limited and IOL Speciality Chemicals Limited were incorporated in June 2022 as wholly owned subsidiaries of the Company and therefore, the figures for consolidated audited financial results for the previous year 2021-22 includes the audited financial results of only IOL- Foundation.
5. An overseas wholly owned subsidiary IOL Global Limited was incorporated on 30<sup>th</sup> January 2023 in United Kingdom and therefore not considered for consolidation.
6. The previous financial period figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board  
IOL Chemicals and Pharmaceuticals Limited



Vikas Gupta  
Joint Managing Director  
DIN: 07198109

Place: Ludhiana  
Date: 28<sup>th</sup> April 2023





**Annexure 2**

**Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated 09<sup>th</sup> September, 2015:**

Sr. No.	Particulars	Details	Details
1.	Name of Director	Mr Varinder Gupta	-
2.	Name of the Statutory Auditor	-	M/s. Ashwani & Associates
3.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Re-appointment	Re-appointment as Statutory Auditors of the Company  The current term of Auditor will expire at the conclusion of ensuing Annual General Meeting (AGM).
	Date of appointment	1 <sup>st</sup> September 2023	From the conclusion of 36 <sup>th</sup> AGM till the conclusion of 41 <sup>st</sup> AGM.
	Term of appointment;	Subject to the approval by the Shareholders at the ensuing AGM, and on the basis of recommendation of the Nomination and Remuneration Committee the Board has re-appointed him as Managing Director for a period of 5 years.	Subject to the approval by the Shareholders at the ensuing AGM, and on the basis of recommendation of the Audit Committee the Board has re-appointed M/s. Ashwani & Associates as Statutory Auditors of the Company for second term of 5 Years from the conclusion of 36 <sup>th</sup> AGM till the conclusion of 41 <sup>st</sup> AGM.
4.	Brief profile (in case of appointment);	Mr Varinder Gupta has experience of about 4 decades of chemical and pharmaceuticals industry. His comprehensive and innovative approach with operational initiatives has been a major factor driving innovation and business excellence in the organization. Under his leadership the Company is performing well and achieving the various business milestones.	M/s Ashwani & Associates, Chartered Accountants, was established in 1978 having head office at Ludhiana with three branches in India. The firm has rich experience of 45 years in providing multidisciplinary services in areas such as Audit & Assurance, Tax and Management Consultancy to various Indian and Foreign Corporations. M/s Ashwani & Associates is an independent member of Geneva Group International (GGI). GGI is a global network of professional, independent accounting, consulting and law firms.
5.	Disclosure of relationships between directors (in case of appointment of a director).	Mr Varinder Gupta is father of Mr Vikas Gupta, Joint Managing Director and Mr Abhiraj Gupta, Executive Director.	Not Applicable.

